Detalles de la búsqueda
1.
Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model.
Drug Metab Dispos
; 43(10): 1417-29, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26180127
2.
Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects.
Xenobiotica
; 45(1): 45-59, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25034009
3.
Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design.
J Drugs Dermatol
; 14(8): 777-84, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26267721
4.
Integrating disease progression models, non-clinical pharmacokinetic data and treatment response endpoints to optimize intravitreal dosing regimens.
Int J Clin Pharmacol Ther
; 52(7): 574-86, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24755127
5.
Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
Drug Metab Dispos
; 41(2): 343-52, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23129213
6.
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
Nat Cancer
; 3(6): 710-722, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35726063
7.
Liver Toxicity Observed With Lorlatinib When Combined With Strong CYP3A Inducers: Evaluation of Cynomolgus Monkey as a Nonclinical Model for Assessing the Mechanism of Combinational Toxicity.
Toxicol Sci
; 182(2): 183-194, 2021 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34021354
8.
Metabolism, Excretion, and Pharmacokinetics of Lorlatinib (PF-06463922) and Evaluation of the Impact of Radiolabel Position and Other Factors on Comparability of Data Across 2 ADME Studies.
J Clin Pharmacol
; 60(9): 1254-1267, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32441835
9.
Effects of Renal Function on Crizotinib Pharmacokinetics: Dose Recommendations for Patients with ALK-Positive Non-Small Cell Lung Cancer.
Clin Drug Investig
; 37(4): 363-373, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28035616
10.
Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.
AAPS J
; 18(5): 1101-1116, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27198897
11.
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab).
Adv Ther
; 33(11): 1964-1982, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27585978
12.
Crizotinib reduces the rate of dark adaptation in the rat retina independent of ALK inhibition.
Toxicol Sci
; 143(1): 116-25, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25326243
13.
RTP801 gene expression is differentially upregulated in retinopathy and is silenced by PF-04523655, a 19-Mer siRNA directed against RTP801.
Invest Ophthalmol Vis Sci
; 55(3): 1232-40, 2014 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-24458146
14.
Intravitreal concentrations of a near-infrared fluorescence-labeled biotherapeutic determined in situ using confocal scanning laser ophthalmoscopy.
Invest Ophthalmol Vis Sci
; 52(9): 6949-58, 2011 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21791590
15.
Rational design of a topical androgen receptor antagonist for the suppression of sebum production with properties suitable for follicular delivery.
J Med Chem
; 53(11): 4422-7, 2010 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-20462217
16.
Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications.
J Med Chem
; 51(21): 7010-4, 2008 Nov 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-18921992
17.
Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production.
Bioorg Med Chem Lett
; 17(20): 5693-7, 2007 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17766112
18.
(1R,2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile, a potent androgen receptor antagonist for stimulating hair growth and reducing sebum production.
Bioorg Med Chem Lett
; 17(21): 5983-8, 2007 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17827000
Resultados
1 -
18
de 18
1
Próxima >
>>